Implied Volatility Surging for TCR2 Therapeutics (TCRR) Stock OptionsZacks Investment Research • 08/18/21
TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/21
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical OfficerGlobeNewsWire • 07/20/21
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/21
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual MeetingGlobeNewsWire • 04/10/21
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/11/21
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor PipelineGlobeNewsWire • 03/10/21
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common StockGlobeNewsWire • 01/20/21
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid TumorsGlobeNewsWire • 12/13/20
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid TumorsGlobeNewsWire • 12/11/20
TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/20
TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/20
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid TumorsGlobeNewsWire • 07/26/20